Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance.
Nuclear factor erythroid-2 related factor 2 (Nrf2), a redox-sensitive transcription factor, regulates the expression of antioxidant enzymes and several anti-apoptotic proteins, which confer cytoprotection against oxidative stress and apoptosis. Constitutive activation of Nrf2 in lung cancer cells promotes tumorigenicity and contributes to chemoresistance by upregulation of glutathione, thioredoxin, and the drug efflux pathways involved in detoxification of electrophiles and broad spectrum of drugs. In this study, we show that RNAi-mediated lowering of Nrf2 levels in non-small-cell lung cancer (NSCLC) cell lines (A549 and H460) led to a dramatic increase in endogenous reactive oxygen species (ROS) levels. Similarly, γ-irradiation-induced formation of protein carbonyls were significantly higher in Nrf2-depleted lung cancer cells, suggesting increased lethality of ionizing radiation in the absence of Nrf2. Radiation-induced protein oxidation in Nrf2shRNA cells correlated with reduced survival as measured by clonogenic assay. Radiation-induced cell death was abrogated by pretreatment with antioxidants such as N-acetyl-L-cysteine, glutathione, and vitamin-E, highlighting the importance of antioxidants in conferring protection against radiation injury. Using genetically-modified gain and loss of function models of Nrf2, in mouse embryonic fibroblasts, we establish that constitutive activation of Nrf2 protects against ionizing radiation toxicity and confers radioresistance. Thus, targeting Nrf2 activity in radioresistant tumors could be a promising strategy to circumvent radioresistance.
Singh
Anju
A
Department of Environmental Health Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Bodas
Manish
M
Wakabayashi
Nobunao
N
Bunz
Fred
F
Biswal
Shyam
S
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism* / Q000532:radiotherapy; D045744:Cell Line, Tumor; D015536:Down-Regulation; D005347:Fibroblasts / Q000528:radiation effects; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D011836:Radiation Tolerance; D017382:Reactive Oxygen Species / Q000378:metabolism
D000975:Antioxidants; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; C495636:Nfe2l2 protein, mouse; D034741:RNA, Small Interfering; D017382:Reactive Oxygen Species
Toxicology. 2003 Jul 15;189(1-2):1-20
12821279
Oncogene. 2003 Dec 18;22(58):9275-81
14681686
Nat Genet. 2003 Nov;35(3):238-45
14517554
PLoS Med. 2006 Oct;3(10):e420
17020408
Science. 2006 Oct 13;314(5797):268-74
16959974
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5742-6
8516323
Mech Ageing Dev. 1998 Jun 1;103(1):45-55
9681878
Arch Biochem Biophys. 2002 Jan 15;397(2):377-83
11795897
Cancer Cell. 2006 Sep;10(3):241-52
16959615
Pharmacol Ther. 1988;39(1-3):301-9
3059373
Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21
17822677
Carcinogenesis. 2002 May;23(5):705-11
12016141
Annu Rev Pharmacol Toxicol. 2007;47:89-116
16968214
J Exp Med. 2005 Jul 4;202(1):47-59
15998787
Biochem J. 2005 Sep 1;390(Pt 2):521-8
15890065
Mol Cell Biol. 2004 Aug;24(16):7130-9
15282312
Mol Cell Biol. 2004 Dec;24(24):10941-53
15572695
Biochem J. 2006 May 1;395(3):599-609
16426233
Ann N Y Acad Sci. 2000;899:44-60
10863528
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4
18692501
J Cell Physiol. 2000 Apr;183(1):100-7
10699971
Cancer Gene Ther. 2010 Feb;17(2):120-30
19730451
Cancer Res. 2002 Sep 15;62(18):5196-203
12234984
Am J Respir Cell Mol Biol. 2006 Dec;35(6):639-50
16794261
Med Res Rev. 2004 Jan;24(1):40-89
14595672
Biochem Biophys Res Commun. 2003 Oct 24;310(3):824-9
14550278
Cancer Res. 2001 May 15;61(10):3986-97
11358816
Oncogene. 1997 Sep 18;15(12):1461-70
9333022
Cancer Res. 2008 Oct 1;68(19):7975-84
18829555
Annu Rev Pharmacol Toxicol. 2003;43:233-60
12359864
Int J Mol Med. 2004 Jun;13(6):883-7
15138630
Mol Cell Biol. 2007 Oct;27(20):7188-97
17709388
Mol Cell. 2006 Mar 3;21(5):689-700
16507366
Cancer Res. 1999 Jun 15;59(12):2829-33
10383141
Biochem Biophys Res Commun. 2006 Dec 29;351(4):883-9
17097057
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13568-73
18757741
Nature. 2009 Apr 9;458(7239):780-3
19194462
Am J Respir Cell Mol Biol. 2007 Jul;37(1):3-8
17413030
Oncogene. 2003 Feb 13;22(6):797-806
12584558
J Clin Invest. 2004 Nov;114(9):1248-59
15520857
Cancer Res. 2007 Jan 15;67(2):546-54
17234762
Free Radic Biol Med. 2007 Jun 15;42(12):1838-50
17512463
Radiat Res. 2000 Jun;153(6):781-7
10825753
Ann N Y Acad Sci. 2001 Apr;928:22-38
11795513
FASEB J. 2001 Jul;15(9):1569-74
11427489